Luis L Ostrosky-Zeichner

List of Publications by Citations

128 papers	15,947 citations	47 h-index	126 g-index
137 ext. papers	18,595 ext. citations	7.3 avg, IF	6.26 L-index

#	Paper	IF	Citations
128	Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2009**, 48, 503-35	11.6	2247
127	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2016**, 62, e1-50	11.6	1655
126	Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. *Clinical Infectious Diseases*, **2016**, 62, 409-17	11.6	1105
125	Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. *Lancet, The*, **2007**, 369, 1519-1527	40	1092
124	Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. *Clinical Infectious Diseases*, **2007**, 45, 883-93	11.6	1030
123	Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. *Clinical Infectious Diseases*, **2020**, 71, 1367-1376	11.6	607
122	Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. *Clinical Infectious Diseases*, **2005**, 41, 654-9	11.6	560
121	Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. *Clinical Infectious Diseases*, **2004**, 39, 199-205	11.6	536
120	Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 3149-54	5.9	438
119	Combination antifungal therapy. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 693-715	5.9	412
118	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. *Lancet Infectious Diseases, The*, **2016**, 16, 828-837	25.5	382
117	Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer consensus criteria. *Clinical Infectious Diseases*, **2008**, 47, 674-83	11.6	308
116	T2 magnetic resonance assay for the rapid diagnosis of candidemia in whole blood: a clinical trial. *Clinical Infectious Diseases*, **2015**, 60, 892-9	11.6	305
115	An insight into the antifungal pipeline: selected new molecules and beyond. *Nature Reviews Drug Discovery*, **2010**, 9, 719-27	64.1	305
114	Amphotericin B: time for a new "gold standard". *Clinical Infectious Diseases*, **2003**, 37, 415-25	11.6	289
113	Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. *European Journal of Clinical Microbiology and Infectious Diseases*, **2007**, 26, 271-6	5.3	277
112	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. *Lancet Infectious Diseases, The*, **2021**, 21, e149-e162	25.5	242

111	Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole. *Antimicrobial Agents and Chemotherapy*, **2003**, 47, 1647-51	5.9	182
110	Invasive candidiasis in the intensive care unit. *Critical Care Medicine*, **2006**, 34, 857-63	1.4	179
109	In vitro antifungal susceptibilities of Trichosporon species. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 1144-6	5.9	170
108	Interlaboratory comparison of results of susceptibility testing with caspofungin against Candida and Aspergillus species. *Journal of Clinical Microbiology*, **2004**, 42, 3475-82	9.7	163
107	Invasive mycoses: diagnostic challenges. *American Journal of Medicine*, **2012**, 125, S14-24	2.4	148
106	Rules for identifying patients at increased risk for candidal infections in the surgical intensive care unit: approach to developing practical criteria for systematic use in antifungal prophylaxis trials. *Medical Mycology*, **2005**, 43, 235-43	3.9	144
105	Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. *Antimicrobial Agents and Chemotherapy*, **2006**, 50, 143-7	5.9	138
104	MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. *Clinical Infectious Diseases*, **2014**, 58, 1219-26	11.6	117
103	Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. *Diagnostic Microbiology and Infectious Disease*, **2011**, 70, 330-43	2.9	106
102	Detecting Infections Rapidly and Easily for Candidemia Trial, Part 2 (DIRECT2): A Prospective, Multicenter Study of the T2Candida Panel. *Clinical Infectious Diseases*, **2018**, 66, 1678-1686	11.6	98
101	Differences in beta-glucan levels in culture supernatants of a variety of fungi. *Medical Mycology*, **2006**, 44, 267-72	3.9	97
100	(1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. *Clinical Infectious Diseases*, **2012**, 55, 521-6	11.6	96
99	Intensive care medicine research agenda on invasive fungal infection in critically ill patients. *Intensive Care Medicine*, **2017**, 43, 1225-1238	14.5	90
98	Invasive candidiasis in immunocompromised hospitalized patients. *Archives of Medical Research*, **2005**, 36, 660-71	6.6	87
97	Improvement of a clinical prediction rule for clinical trials on prophylaxis for invasive candidiasis in the intensive care unit. *Mycoses*, **2011**, 54, 46-51	5.2	85
96	Prospective survey of (1->3)-beta-D-glucan and its relationship to invasive candidiasis in the surgical intensive care unit setting. *Journal of Clinical Microbiology*, **2011**, 49, 58-61	9.7	83
95	Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial. *Clinical Infectious Diseases*, **2019**, 68, 1981-1989	11.6	81
94	Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT1): A Prospective, Multicenter Study of the T2Candida Panel. *Open Forum Infectious Diseases*, **2017**, 4, S52-S52	1	78

93	2045. Pitfalls in the Use of MALDI TOF Mass Spectrometry for the Identification of Problematic Yeast Isolates from a Historical Collection. *Open Forum Infectious Diseases*, **2018**, 5, S596-S597	1	78
92	What's new in the clinical and diagnostic management of invasive candidiasis in critically ill patients. *Intensive Care Medicine*, **2014**, 40, 808-19	14.5	75
91	Early treatment of candidemia in adults: a review. *Medical Mycology*, **2011**, 49, 113-20	3.9	67
90	In vitro activity of anidulafungin against selected clinically important mold isolates. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 1912-5	5.9	67
89	Cost of a ventilator-associated pneumonia in a shock trauma intensive care unit. *Surgical Infections*, **2005**, 6, 65-72	2	65
88	In vitro activities of investigational triazoles against Fusarium species: effects of inoculum size and incubation time on broth microdilution susceptibility test results. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3298-300	5.9	64
87	In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp. *Antimicrobial Agents and Chemotherapy*, **2005**, 49, 3572-4	5.9	63
86	Current options in antifungal pharmacotherapy. *Pharmacotherapy*, **2008**, 28, 614-45	5.8	60
85	Effects of serum on in vitro susceptibility testing of echinocandins. *Antimicrobial Agents and Chemotherapy*, **2007**, 51, 4214-6	5.9	60
84	New approaches to the risk of Candida in the intensive care unit. *Current Opinion in Infectious Diseases*, **2003**, 16, 533-7	5.4	57
83	Correlation of clinical outcomes with □-glucan levels in patients with invasive candidiasis. *Journal of Clinical Microbiology*, **2012**, 50, 2104-6	9.7	48
82	Pharmacokinetic evaluation of single-dose intravenous daptomycin in patients with thermal burn injury. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1891-3	5.9	48
81	Deeply invasive candidiasis. *Infectious Disease Clinics of North America*, **2002**, 16, 821-35	6.5	46
80	Tigecycline : a critical safety review. *Expert Opinion on Drug Safety*, **2015**, 14, 335-42	4.1	45
79	Thinking beyond the Common Candida Species: Need for Species-Level Identification of Candida Due to the Emergence of Multidrug-Resistant Candida auris. *Journal of Clinical Microbiology*, **2017**, 55, 3324-3327	9.7	44
78	Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. *International Journal of Antimicrobial Agents*, **2015**, 45, 541-4	14.3	43
77	Drugs in Clinical Development for Fungal Infections. *Drugs*, **2017**, 77, 1505-1518	12.1	41
76	Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium. *Journal of Infectious Diseases*, **2020**, 222, S175-S198	7	39

75	Successful use of amphotericin B lipid complex in the treatment of cryptococcosis. *Clinical Infectious Diseases*, **2005**, 40 Suppl 6, S409-13	11.6	38
74	Peritonitis due to Aspergillus and zygomycetes in patients undergoing peritoneal dialysis: report of 2 cases and review of the literature. *Diagnostic Microbiology and Infectious Disease*, **2003**, 46, 49-54	2.9	37
73	In vitro activity of nystatin compared with those of liposomal nystatin, amphotericin B, and fluconazole against clinical Candida isolates. *Journal of Clinical Microbiology*, **2002**, 40, 1406-12	9.7	36
72	Liposuction for protease-inhibitor-associated lipodystrophy. *Lancet, The*, **1999**, 353, 1244	40	36
71	Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 4175-7	5.9	35
70	Contemporary treatment and outcomes of zygomycosis in a non-oncologic tertiary care center. *Archives of Medical Research*, **2007**, 38, 90-3	6.6	35
69	Correlation between microdilution, E-test, and disk diffusion methods for antifungal susceptibility testing of posaconazole against Candida spp. *Journal of Clinical Microbiology*, **2006**, 44, 2105-8	9.7	33
68	MSG-10: a Phase 2 study of oral ibrexafungerp (SCY-078) following initial echinocandin therapy in non-neutropenic patients with invasive candidiasis. *Journal of Antimicrobial Chemotherapy*, **2019**, 74, 3056-3062	5.1	29
67	Multilaboratory testing of two-drug combinations of antifungals against Candida albicans, Candida glabrata, and Candida parapsilosis. *Antimicrobial Agents and Chemotherapy*, **2011**, 55, 1543-8	5.9	29
66	Neurocysticercosis and HIV infection: report of two cases and review. *World Neurosurgery*, **1996**, 45, 57-61		29
65	A Mycoses Study Group International Prospective Study of Phaeohyphomycosis: An Analysis of 99 Proven/Probable Cases. *Open Forum Infectious Diseases*, **2017**, 4, ofx200	1	28
64	Clinical Characteristics and Predictors of Adverse Outcome in Adult and Pediatric Patients With Healthcare-Associated Ventriculitis and Meningitis. *Open Forum Infectious Diseases*, **2016**, 3, ofw077	1	28
63	Pharmacokinetics of intravenous itraconazole in stable hemodialysis patients. *Antimicrobial Agents and Chemotherapy*, **2004**, 48, 3151-3	5.9	28
62	Invasive Fungal Infections in the Intensive Care Unit. *Infectious Disease Clinics of North America*, **2017**, 31, 475-487	6.5	27
61	Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12). *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3536-3539	5.1	27
60	Isavuconazole for treatment of rare invasive fungal diseases. *Mycoses*, **2018**, 61, 518-533	5.2	26
59	Multilaboratory testing of antifungal combinations against a quality control isolate of Candida krusei. *Antimicrobial Agents and Chemotherapy*, **2008**, 52, 1500-2	5.9	24
58	Effect of the echinocandin caspofungin on expression of Candida albicans secretory aspartyl proteinases and phospholipase in vitro. *Antimicrobial Agents and Chemotherapy*, **2002**, 46, 3096-100	5.9	23

57	Pharmacoeconomics of antifungal pharmacotherapy--challenges and future directions. *Expert Opinion on Pharmacotherapy*, **2005**, 6, 2617-32	4	22
56	Syscan3, a kit for detection of anti-Candida antibodies for diagnosis of invasive candidiasis. *Journal of Clinical Microbiology*, **2005**, 43, 4834-5	9.7	22
55	Rezafungin Versus Caspofungin in a Phase 2, Randomized, Double-blind Study for the Treatment of Candidemia and Invasive Candidiasis: The STRIVE Trial. *Clinical Infectious Diseases*, **2021**, 73, e3647-e3655	11.6	22
54	Surveillance of Candida spp bloodstream infections: epidemiological trends and risk factors of death in two Mexican tertiary care hospitals. *PLoS ONE*, **2014**, 9, e97325	3.7	21
53	Early antifungal intervention strategies in ICU patients. *Current Opinion in Critical Care*, **2010**, 16, 465-9	3.5	21
52	Isavuconazole for treatment of invasive fungal diseases caused by more than one fungal species. *Mycoses*, **2018**, 61, 485-497	5.2	20
51	Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. *International Journal of Antimicrobial Agents*, **2004**, 24, 346-51	14.3	20
50	Invasive Candidiasis. *Seminars in Respiratory and Critical Care Medicine*, **2020**, 41, 3-12	3.9	19
49	Fatal amphotericin B overdose due to administration of nonlipid formulation instead of lipid formulation. *Pharmacotherapy*, **2005**, 25, 426-8	5.8	18
48	Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial. *Mycoses*, **2018**, 61, 420-429	5.2	17
47	Therapy of common superficial fungal infections. *Dermatologic Therapy*, **2004**, 17, 517-22	2.2	17
46	Differential antifungal activity of isomeric forms of nystatin. *Antimicrobial Agents and Chemotherapy*, **2001**, 45, 2781-6	5.9	15
45	Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM. *Lancet Infectious Diseases, The*, **2021**, 21, e375-e386	25.5	15
44	The Role of In Vitro Susceptibility Testing in the Management of Candida and Aspergillus. *Journal of Infectious Diseases*, **2017**, 216, S452-S457	7	13
43	Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial.. *JAMA Internal Medicine*, **2021**,	11.5	13
42	Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis. *BMC Infectious Diseases*, **2017**, 17, 753	4	11
41	Clinical prediction rules for invasive candidiasis in the ICU: ready for prime time?. *Critical Care*, **2011**, 15, 189	10.8	11
40	Activity of anidulafungin in a murine model of Candida krusei infection: evaluation of mortality and disease burden by quantitative tissue cultures and measurement of serum (1,3)-beta-D-glucan levels. *Antimicrobial Agents and Chemotherapy*, **2009**, 53, 1639-41	5.9	11

39	Evaluation of BacT/Alert FA Blood Culture Bottles and T2Candida Assay for Detection of Candida in the Presence of Antifungals. *Journal of Clinical Microbiology*, **2018**, 56,	9.7	10
38	Coronavirus Disease 2019-Associated Invasive Fungal Infection. *Open Forum Infectious Diseases*, **2021**, 8, ofab510	1	10
37	Seroprevalence of Strongyloides stercoralis and Evaluation of Universal Screening in Kidney Transplant Candidates: A Single-Center Experience in Houston (2012-2017). *Open Forum Infectious Diseases*, **2019**, 6,	1	8
36	Progressive Dispersion of Azole Resistance in Aspergillus fumigatus: Fatal Invasive Aspergillosis in a Patient with Acute Myeloid Leukemia Infected with an A. fumigatus Strain with a TR Y121F M172I T289A Allele. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	8
35	A Risk Score for Fluconazole Failure among Patients with Candidemia. *Antimicrobial Agents and Chemotherapy*, **2017**, 61,	5.9	7
34	Povidone-iodine solution as SARS-CoV-2 prophylaxis for procedures of the upper aerodigestive tract a theoretical framework. *Journal of Otolaryngology - Head and Neck Surgery*, **2020**, 49, 77	5.4	7
33	Investigational Agents for the Treatment of Resistant Yeasts and Molds. *Current Fungal Infection Reports*, **2021**, 15, 1-12	1.4	7
32	Point-Counterpoint: Should Serum □d-Glucan Testing Be Used for the Diagnosis of Pneumocystis jirovecii Pneumonia?. *Journal of Clinical Microbiology*, **2019**, 58,	9.7	6
31	Issues in the design and interpretation of antifungal drug trials in the critically ill. *Current Opinion in Infectious Diseases*, **2009**, 22, 564-7	5.4	5
30	1718. Rezafungin Clinical Safety and Efficacy in Patients With Candidemia and/or Invasive Candidiasis in the Randomized, Double-Blind, Multicenter, Phase 2 STRIVE Study. *Open Forum Infectious Diseases*, **2018**, 5, S52-S52	1	5
29	Post-exposure prophylaxis with isavuconazole after occupational exposure to. *Oxford Medical Case Reports*, **2018**, 2018, omy062	0.6	4
28	New serological markers in medical mycology: (1,3)-(-D-glucan and Aspergillus galactomannan. *Infectio*, **2012**, 16, 59-63	0.7	3
27	Update on the Diagnosis of Candidemia and Invasive Candidiasis. *Current Fungal Infection Reports*, **2019**, 13, 301-307	1.4	3
26	Screening donors for COVID-19 convalescent plasma. *Transfusion*, **2021**, 61, 1047-1052	2.9	3
25	Antifungal Susceptibility Testing: Evolution, Indications, and Role in Clinical Practice. *Current Treatment Options in Infectious Diseases*, **2015**, 7, 155-162	1	2
24	Fungal Infections. *Infectious Disease Clinics of North America*, **2016**, 30, xiii-xiv	6.5	2
23	Novel approaches to antifungal prophylaxis. *Expert Opinion on Investigational Drugs*, **2004**, 13, 665-72	5.9	2
22	113. Accuracy of the NHSN Central Line-Associated Bloodstream Infection (CLABSI) Definition. *Open Forum Infectious Diseases*, **2018**, 5, S3-S3	1	2

21	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non-fumigatus): A multicentre, non-interventional registry study. *Mycoses*, **2021**,	5.2	2
20	High-Dose Caspofungin is Safe for Adult Patients with Invasive Candidiasis. *Current Fungal Infection Reports*, **2011**, 5, 1-2	1.4	1
19	Invasive candidiasis in the intensive care unit. *Hospital Practice (1995)*, **2010**, 38, 82-91	2.2	1
18	Antifungal and Antiviral Therapy **2008**, 1089-1109		1
17	Anidulafungin: a new addition to the antifungal armamentarium. *Therapy: Open Access in Clinical Medicine*, **2007**, 4, 125-132		1
16	Invasive Yeast Infections. *Infectious Disease and Therapy*, **2007**, 221-238		1
15	Neonatal Fungal Infections **2012**, 287-302		1
14	Lymphatic Dissemination and Axillary Web Syndrome in Primary Cutaneous Tuberculosis Secondary to Needlestick Injury. *Open Forum Infectious Diseases*, **2021**, 8, ofab160	1	1
13	Epidemiology and Management of Candidiasis in Solid Organ Transplant Recipients. *Current Fungal Infection Reports*, **2016**, 10, 147-152	1.4	1
12	Reprocessing N95s with hydrogen peroxide vaporization: A robust system from collection to dispensing. *American Journal of Infection Control*, **2021**, 49, 508-511	3.8	1
11	369. Using Hybrid Models and Blockchain Technology as a Means to Develop a Novel Propensity Score for Candidemia and Invasive Candidiasis. *Open Forum Infectious Diseases*, **2018**, 5, S144-S145	1	1
10	Furuncular myiasis in a traveller to West Africa. *Journal of Travel Medicine*, **2021**, 28,	12.9	0
9	Prevention and Treatment of Yeast and Endemic Fungal Infections **2019**, 179-199		
8	40 years of medical mycology at JAC. *Journal of Antimicrobial Chemotherapy*, **2016**, 71, 3327-3329	5.1	
7	Can fungal biomarkers be used to improve antifungal therapy in the intensive care unit?. *Current Fungal Infection Reports*, **2009**, 3, 147-151	1.4	
6	Neonatal Fungal Infections **2008**, 262-278		
5	Prophylaxis for Candida in the intensive care unit patient. *Current Fungal Infection Reports*, **2008**, 2, 69-73	1.4	
4	Fungal and Parasitic Infections **2009**, 113-134		

3	New Developments in Diagnostics and Management of Invasive Candidiasis443-448	
2	Measles or Not Measles? That Is the Question!. *Open Forum Infectious Diseases*, **2020**, 7, ofaa311	1
1	Fungal Diagnostics: A Practical Approach. *Current Clinical Microbiology Reports*, **2016**, 3, 103-110	3.1